Daré Bioscience, Inc. (NASDAQ:DARE) Sees Large Growth in Short Interest

Daré Bioscience, Inc. (NASDAQ:DARE) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 38,800 shares, a growth of 9.6% from the September 15th total of 35,400 shares. Based on an average daily volume of 39,300 shares, the short-interest ratio is presently 1.0 days. Currently, 0.5% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a report on Wednesday, August 14th.

Institutional Trading of Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC increased its holdings in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the period. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 6.70% of the company’s stock.

Daré Bioscience Stock Performance

Shares of DARE traded up $0.02 during trading hours on Thursday, hitting $3.60. The stock had a trading volume of 21,076 shares, compared to its average volume of 45,827. The firm has a 50-day moving average price of $3.40 and a 200 day moving average price of $4.06. Daré Bioscience has a fifty-two week low of $3.05 and a fifty-two week high of $7.56. The firm has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.93 and a beta of 1.39.

Daré Bioscience (NASDAQ:DARE) last posted its earnings results on Monday, August 12th. The biotechnology company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $2.09. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.60 million. As a group, analysts predict that Daré Bioscience will post -0.27 EPS for the current fiscal year.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.